Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

NCT01915303 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushings Disease

Interventions

DRUG: Pasireotide with or without cabergoline

Sponsor

Novartis Pharmaceuticals